Avrobio Plots Plan B After Fabry Disease Gene Therapy Problems

Lead Candidate Shelved

 
• By Andrew McConaghie

Avrobio is sidestepping market and regulatory issues in Fabry disease by suspending development of AVR-RD-01, but says it remains focused on advancing treatment of lysosomal storage disorders with gene therapies.

DNA helix
The company's ex vivo lentiviral gene therapy platform has hit an obstacle in Fabry disease - but it hopes other rare diseases will deliver. • Source: Alamy

More from R&D

More from Scrip